Meridith Morgan, Ph.D.
Assistant Professor, Department of Radiation Oncology
Dr. Morgan received her Ph.D. in Genetics and Developmental Biology in 2002 from West Virginia University. She completed her post-doctoral training in Radiation Biology under the mentorship of Dr. Ted Lawrence at the University of Michigan during which she developed CHK1 inhibitors as chemoradiation sensitizers. In 2009, Dr. Morgan was appointed Assistant Professor of Radiation Oncology at the University of Michigan and continued her research efforts in the fields of the DNA damage response and experimental therapeutic radiation sensitizers. In 2014, Dr. Morgan successfully translated her preclinical laboratory research to a clinical trial in patients with pancreatic cancer. Dr. Morgan runs an NIH-funded laboratory and trains undergraduate, medical and graduate students, as well as post-doctoral and medical fellows.
Dr. Morgan leads a laboratory focused on improving standard radiation and chemoradiation therapies through the use of novel agents targeting DNA damage response and repair. Her research program prioritizes pre-clinical research with strong clinical/translational relevance with an emphasis on pancreatic cancer. More specific areas of research interest include DNA double-strand break repair, DNA replication, cell cycle and immunotherapy.